These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 10754991)

  • 41. Metastatic adult-type non-rhabdomyosarcoma soft tissue sarcomas in children and adolescents: A cohort study from the European paediatric Soft tissue sarcoma Study Group.
    Ferrari A; Orbach D; Casanova M; van Noesel MM; Berlanga P; Brennan B; Corradini N; Schoot RA; Ramirez-Villar GL; Hjalgrim LL; Alaggio R; Guillen Burrieza G; Safwat A; Cameron AL; van Rijn RR; Minard-Colin V; Zanetti I; Bisogno G; Chisholm JC; Merks JHM
    Cancer; 2023 Aug; 129(16):2542-2552. PubMed ID: 37084075
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical patterns of soft-tissue sarcoma in children].
    Méndez R; Arnáiz S; Montero M; Tellado M; País E; Ríos J; Vela D
    Cir Pediatr; 2001 Jan; 14(1):14-20. PubMed ID: 11339112
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
    Heinz AT; Schönstein A; Ebinger M; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter M; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Ljungman G; Juntti H; Klingebiel T; Koscielniak E; Sparber-Sauer M;
    Pediatr Blood Cancer; 2024 Jan; 71(1):e30707. PubMed ID: 37814424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of pelvic sarcomas in adolescents and young adults with intensive combined modality therapy.
    Stea B; Kinsella TJ; Triche TJ; Horvath K; Glatstein E; Miser JS
    Int J Radiat Oncol Biol Phys; 1987 Dec; 13(12):1797-805. PubMed ID: 3679916
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan AA; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
    J Clin Oncol; 2014 Nov; 32(31):3547-52. PubMed ID: 25267746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rhabdomyosarcoma and other soft tissue sarcomas of childhood.
    Goren MP
    Curr Opin Oncol; 1991 Aug; 3(4):677-83. PubMed ID: 1932227
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
    J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pediatric soft tissue sarcomas.
    Wexler LH; Helman LJ
    CA Cancer J Clin; 1994; 44(4):211-47. PubMed ID: 8019928
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS)-I.
    Raney RB; Tefft M; Maurer HM; Ragab AH; Hays DM; Soule EH; Foulkes MA; Gehan EA
    Cancer; 1988 Oct; 62(7):1257-66. PubMed ID: 2843274
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee.
    Orbach D; Rey A; Oberlin O; Sanchez de Toledo J; Terrier-Lacombe MJ; van Unnik A; Quintana E; Stevens MC
    J Clin Oncol; 2005 Jul; 23(19):4363-71. PubMed ID: 15994146
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.
    Baker KS; Anderson JR; Link MP; Grier HE; Qualman SJ; Maurer HM; Breneman JC; Wiener ES; Crist WM
    J Clin Oncol; 2000 Jun; 18(12):2427-34. PubMed ID: 10856103
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
    Gallego S; Zanetti I; Orbach D; Ranchère D; Shipley J; Zin A; Bergeron C; de Salvo GL; Chisholm J; Ferrari A; Jenney M; Mandeville HC; Rogers T; Merks JHM; Mudry P; Glosli H; Milano GM; Ferman S; Bisogno G;
    Cancer; 2018 Aug; 124(15):3201-3209. PubMed ID: 29797665
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma?
    Blakely ML; Lobe TE; Anderson JR; Donaldson SS; Andrassy RJ; Parham DM; Wharam MD; Qualman SJ; Wiener ES; Grier HE; Crist WM
    J Pediatr Surg; 1999 May; 34(5):736-41; discussion 741-2. PubMed ID: 10359174
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Soft-tissue sarcomas in the young: medical treatment advances in perspective.
    Jenkin D; Sonley M
    Cancer; 1980 Aug; 46(3):621-9. PubMed ID: 7190463
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rhabdomyosarcoma and other soft tissue sarcomas of childhood.
    Pappo AS
    Curr Opin Oncol; 1994 Jul; 6(4):397-402. PubMed ID: 7803541
    [TBL] [Abstract][Full Text] [Related]  

  • 56. What is new in rhabdomyosarcoma management in children?
    Gosiengfiao Y; Reichek J; Walterhouse D
    Paediatr Drugs; 2012 Dec; 14(6):389-400. PubMed ID: 23050743
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neonatal soft tissue sarcomas.
    Ferrari A; Orbach D; Sultan I; Casanova M; Bisogno G
    Semin Fetal Neonatal Med; 2012 Aug; 17(4):231-238. PubMed ID: 22633289
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
    Spunt SL; Smith LM; Ruymann FB; Qualman SJ; Donaldson SS; Rodeberg DA; Anderson JR; Crist WM; Link MP
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6072-9. PubMed ID: 15447992
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
    Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
    Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: a report from the Children's Oncology Group.
    Raney B; Huh W; Hawkins D; Hayes-Jordan A; Million L; Rodeberg D; Teot L; Anderson J;
    Pediatr Blood Cancer; 2013 Mar; 60(3):371-6. PubMed ID: 22961750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.